Author + information
- Kazuyuki Maeda,
- Tomofumi Mizuno,
- Hiroaki Takashima,
- Kenji Asai,
- Yasuo Kuroda,
- Katsuhisa Waseda,
- Takashi Kosaka,
- Yasushi Kuhara,
- Akiyoshi Kurita,
- Shinichirou Sakurai,
- Daiki Kato,
- Toru Niwa and
- Tetsuya Amano
We have previously reported that the carperitide, widely used ANP in Japan, can prevent the increase of serum creatinine (sCr) at 1 month after angiography. However, the influence of that effect on chronic outcomes is unknown.
The chronic outcomes after angiography were investigated in the patients who recruited in our previous randomized control trial to prove the renal protecting effect of carperitide from contrast media in patients with CKD (eGFR < 60 ml/min/1.73m2). In the trial, patients received either carperitide and saline (ANP group; carperitide 0.0125µg/kg/min, saline 1ml/kg/hour, n=53) or saline alone (Control group; saline 1ml/kg/hour, n=41) from 12 hour before angiography and continued for 12 hour.
After follow–up period of 817±248 days, sCr was significantly lower in ANP group than in Control group (1.21±0.36 mg/dl vs. 1.51±0.75 mg/dl; p=0.014). The incidence of cardiovascular event (cardiovascular death, heart failure hospitalization, stroke and dialysis) was significantly lower in ANP group than in Control group (5.9% vs. 22.2%; p=0.024). In analysis using Cox proportional hazards models, including Control group, baseline Hb, BNP, HbA1c, BS and Cr, Control group (HR 6.222, p=0.028) and high BNP (HR 1.004, p=0.006) were independent risk factors of cardiovascular event.
Preventing renal damage from contrast media using carperitide is one of the useful methods to improve the chronic outcomes in CKD patients.
Poster Sessions, Expo North
Saturday, March 09, 2013, 3:45 p.m.–4:30 p.m.
Session Title: Complex Patients, Diabetes and Renal Insufficiency
Abstract Category: 43. TCT@ACC–i2: Complex Patients, Diabetes, Renal Insufficiency
Presentation Number: 2106–230
- 2013 American College of Cardiology Foundation